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A B S T R A C T
Background: Intrahepatic cholangiocarcinoma (IHCC) is the second most frequently developed primary
carcinoma of liver, after hepatocellular carcinoma (HCC). They are biologically aggressive and they are
frequently discovered in late study. Surgical removal is the only curative therapeutic method for treat-
ment of such tumors.
Patients and methods: From 1.1.2004 to 31.12.2014, at the Department of Surgery, University Hospital
Martin and Jessenius Medical Faculty of Comenius University in Martin, we operated 411 patients with
benign, primary, metastatic tumors of liver, where in 33 patients (8%) the histology conﬁrmed the primary
intrahepatic cholangiocarcinoma of liver. In the group, we evaluated the 1-year and 5-year survival of the
patients according to radical resections, the degree of differentiation of tumor (grading), and according to
positivity of lymph node. The results were statistically analyzed by the Student t-test and Kaplan–Meier
curves of survival.
Results: The average age of the patients was 59.6 ± 11.4 years, the males represented 46.2%, the females
represented 53.8%. The average age of males was 58 ± 13.2, and females 61 ± 9.8 years. Large anatomic
resections of 3 and more segments of liver were performed in 24 patients, anatomic resections and
metastasectomies were performed in 6 patients, two patients had radiofrequency ablation of tumor. R0
resection was achieved in 20 patients, R1 resection in 8 patients, and R2 resection in 5 patients. One-
year survival in the R0 group was 65%, in the R1 group 62%, and in the R2 resections group it was only
20%; ﬁve-year survival after R0 resections was 52%, and in R1 and R2 it was zero, which proved to be
statistically signiﬁcant. The median of survival in R0 resections was 12 months (interval 1–87 months),
in R1 resections it was 12 months (interval 1–36 months), and after R2 resections it was 7 months (in-
terval 1–12 months). One-year and ﬁve-year survival, depending on the degree of differentiation, was
statistically non-signiﬁcant; however, the ﬁve-year survival of G1 tumors is on the level of being statis-
tically signiﬁcant – the 5-year survival expressed in percentage G1/G2/G3 was 50%/12%/0% respectively.
Positive lymph nodes were found in 16 patients (48%) from the group of 33 patients. The one-year and
ﬁve-year survival was not statistically signiﬁcant; however, 5 years of survival was recorded in 30% pa-
tients with negative lymph node and 0% patients with positivity of lymph node.
Conclusion: Resection of tumor is the optional method; it should be attempted to achieve R0 resection
and at the same time to preserve suﬃcient volume of residual functional parenchyma. Radical R0 resection
is considered by us as the only possible method of surgical treatment for survival of patients with IHCC.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
1.1. Background
Intrahepatic cholangiocarcinoma (IHCC) is the second most fre-
quently developed primary carcinoma of liver, after hepatocellular
carcinoma (HCC). It is developed from the biliary epithelium cells
of intrahepatic bile duct above the second branching of the right
and left lobe. They are biologically aggressive, are frequently found
in late study or are manifested only by distant metastases. Surgi-
cal removal is the only curative therapeutic method for such tumors.
They represent approx. 10% of malign tumors of liver. The inci-
dence and mortality for IHCC in the last years is growing, contrary
to extrahepatic cholangiocarcinoma (EHCC), the occurrence of which
has the tendency to fall down. However, it should be noted that both
IHCC and EHCC may have almost the same microscopic morphol-
ogy, and therefore, perihilar cholangiocarcinomas are frequently
considered as IHCC. The incidence of IHCC in the U.S.A. is approx.
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0.85 cases per 100,000 inhabitants, but for example in Thailand it
is 96 cases per 100,000 inhabitants, which represents 100 multi-
ply. Obligatory precancerosis is primary sclerosing cholangitis (PSC)
and IHCC develops in 8%–40% cases during 10–20 years. The other
precanceroses include congenital biliary cystic disease, parasitical
and bacterial infections, cirrhosis, HBV, HCV infections, and benign
tumors of bile duct, as cystadenoma and papilloma.
From the pathogenic aspect, chronic inﬂammation represents an
important component of many risk factors and is also connected
with malign transformation of biliary epithelium. Chronic inﬂam-
mation damages the DNA cholangiocytes with simultaneous
stimulation of the cell proliferation, whichmay lead to malign trans-
formation. That process leads to increased expression of oncogenes
and reduced expression of the genes suppressing tumor.
In addition to the history and complete clinical examination,
the diagnostics should include mainly biochemical examinations
– bilirubin, hepatal ensymes, oncomarkers, and radiologic imaging
methods. In addition to the scope of the tumor disease, we must
determine the function of liver and functional reserve thereof. Meta-
static intervention to liver by other tumors should also be excluded.
Pre-operation biopsy is recommended as routine only for non-
resectable tumors, otherwise it is not recommended due to tumor
dissemination before resection. Some authors recommend staging
laparoscopy in order to exclude extrahepatic dissemination of tumor.
From oncomarkers, CA19-9 are used in the diagnostics. However,
the serum level of CA19-9 is increased not only in case of
cholangiocarcinoma, but also in case of carcinomas of the upper
gastrointestinal tract, in smokers, in case of cholangoitis and
cholestasis. The level of CA19-9 above 150 U/ml is considered as
an independent negative prognostic factor for perihilar
cholangiocarcinoma [1]. From the other oncomarkers, determina-
tion of serum levels of CEA, IL 6, Trypsinogen II and others is applied,
but their sensitivity and speciﬁcity is lower. From the imaging
method, spiralCT5 with three-stage contrast, MR, MRCP and PET-
CT are appropriate. PET-CT is useful mainly in detection of recurrence,
detection of affected lymph node (LG), and distant metastases. In
classiﬁcation of IHCC and staging of the system, TNM classiﬁca-
tion or Yamasaki classiﬁcation (Liver Cancer Study Group of Japan)
is applied. The evaluation includes the number of lesions, the size
thereof, inﬁltration of the portal and hepatic vein, and growing
into capsule. It is important to determine the level of differentia-
tion of the tumor, which is divided, from the pathologic aspect, to
G1 (well differentiated cholangiocarcinoma, G2 (medium differen-
tiated cholangiocarcinoma), and G3 (low differentiated
cholangiocarcinoma).
1.2. Objectives
First objective of this work is to determine the beneﬁts of sur-
gical treatment of cholangiocarcinoma in our set of patients. The
second objective is to determine the survival of patients with
cholangiocarcinoma according to type of resection and differenti-
ation of the tumor.
2. Material and methods
2.1. Study design
This is a retrospective analysis of patients who underwent sur-
gical treatment of cholangiocarcinoma at Department of Surgery
and Transplantation Center, University Hospital Martin.
2.2. Setting
From 1.1.2004 to 31.12.2014, at the Department of Surgery and
Transplantation Center, University Hospital Martin, we operated 411
patients with benign, primary, metastatic tumors of liver, where in
33 patients (8%) the histology conﬁrmed the primary intrahepatic
cholangiocarcinoma of liver (Fig. 1).
We evaluated the 1-year and 5-year survival of the patients ac-
cording to radicality of resections, the level of differentiation of tumor
(grading), and according to positivity of lymph node.
In the statistical analysis, we applied the certiﬁed statistic program
MedCalc version 13.1.2. and the following statistical analyses: Student
t-test, Kaplan–Meier curves of survival. The value of P < 0.05 is con-
sidered statistically signiﬁcant.
3. Results
The average age of the patients was 59.6 ± 11.4 years; the males
represented 46.2%, the females represented 53.8%. The average age
of males was 58 ± 13.2, and females 61 ± 9.8 years.
Large anatomic resections of 3 segments of liver and more were
performed in 24 patients, anatomic resections andmetastasectomies
were performed in 6 patients, 2 patients had radiofrequency abla-
tion of tumor.
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Fig. 1. Distribution of whole set by histology.
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R0 resection was achieved in 20 patients, R1 resection in 8 pa-
tients, and R2 resection in 5 patients (Fig. 2).
One-year survival and ﬁve-year survival of the patients depend-
ing on the radicality of resection are shown in Figs. 3 and 4. One-
year survival in the R0 group was 65%, in the R1 group 62%, and in
the R2 resections group it was only 20%. Five-year survival after R0
resections was 52% and in R1 and R2 it was zero, which proved to
be statistically signiﬁcant. The median of survival in R0 resections
was 12 months (interval 1–87 months), in R1 resections it was 12
months (interval 1–36 months), and after R2 resections it was 7
months (interval 1–12 months).
Grading of G1 tumors was in 8 patients, G2 in 8 patients, and
G3 in 17 patients. The one-year and ﬁve-year survival depending
on the level of differentiation of tumor is shown in Figs. 5 and 6.
Although the survival of the individual groups of patients is statis-
tically not signiﬁcant, the ﬁve-year survival of G1 tumors is on the
limit of statistical signiﬁcance. The 5-year survival expressed in per-
centage of G1/G2/G3 was 50%/12%/0% respectively.
Positive lymph nodes were detected in 16 patients (48%) in the
group of 33 patients. The one-year and ﬁve-year survival are shown
in Figs. 7 and 8. Although the survival of the individual groups of
patients is statistically not signiﬁcant, 30% of patients with nega-
tive lymph node and 0% of patients with positivity of lymph node
survive for 5 years.
4. Discussion
Treatment of IHCC is primarily surgical. Resection of tumor is
an elected method; the doctors should try to achieve R0 resection
and at the same time to preserve suﬃcient volume of the residual
functional parenchyma. In case of extensive tumors, we may apply
embolization of vena portae or ALPPS (Associating Liver Partition
and Portal vein Ligation for Staged hepatectomy – double resec-
tion of liver with ligature of v. portae onside of tumor). In order to
achieve R0 resection, extensive hepatectomy is frequently made,
which in case of correct indication and non-complicated surgery
do not shorten the survival in spite of higher risk of post-operation
complications [2]. In our group of patients, radical extensive resec-
tions of tumors were dominating – they were performed in more
than one half of the patients. Radical R0 resection is considered by
us as the only possible method of surgical effect on survival of pa-
tients with IHCC. Survival of non-treated patients is less than 5
20, 61%
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Fig. 2. Distribution of patients depending on the radicality of resection.
Fig. 3. One-year survival of patients with IHCC depending on the radicality of
resection.
Fig. 4. Five-year survival of patients with IHCC depending on the radicality of
resection.
Fig. 5. One-year survival of patients depending on the tumor grading.
Fig. 6. Five-year survival of patients depending on the tumor grading.
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months, and R2 resection has the median of survival in the dura-
tion of 3–7months, thus the cytoreductive treatment is not effective.
In contrast, the 5-year survival of the patients with complete re-
section is between 13% and 60%; in our group it was 52%. The reason
of such variability of survival includes also the affected lymph node,
which leads to shortening thereof [3]. Although in our group it was
statistically non-signiﬁcant, the 5-year survival of patients was lower
when expressed in percentage. The discussed issue is whether the
routine lymphadenectomy prolongs the survival of patients with
IHCC or has no effect on survival. For many departments, the af-
fected lymph node represents contraindication for resection [4].
Generally, it may be said that the negative prognostic factors of sur-
vival of patients with IHCC after resection are considered to be the
positive resection edge, the growth type of tumor, vascular inva-
sion, metastases in lymph node, and increased levels of CA19-9
oncomarker [5,6]. The R1 resection and the positive resection edge
are the termswhich should be explained andmore precisely deﬁned.
Positivity of the resection edge in the literature is said to be between
15% and 68% of patients with IHCC [7]. In our group, the micro-
scopic positive edge after resection was in 8 patients (24%). The
suﬃcient resection edge is the only prognostically negative risk factor
which may be directly affected by surgeons. In respect of the pe-
ripheral types of IHCC, it is possible to more precisely deﬁne the
resection edge in the tumors placed centrally and inﬁltrating hilus
of liver, where radicality of resection is more limited by the hilar
structures with more frequent presence of microscopic positivity
of the resection edge in the given site. Very frequently, it is com-
bined with positivity of hilar lymph node. For R0 resection, the
distance of the edge of tumor from the resection line of 10 mm is
considered as suﬃcient; however, this cannot be precisely applied
for tumors inﬁltrating the hilus of liver. The analyses of our group
of patients show that the centrally placed IHCC had positive resec-
tion edges and positivity of lymph node.
Transplantation of liver is not a routine therapeutic method, al-
though the latest studies refer to signiﬁcantly improved survival after
orthotopic transplantations: 5-year survival is even 23%. However,
the condition is absence of extrahepatic dissemination. The con-
tinuing problem is the lack of more effective neoadjuvant and
adjuvant chemotherapy before and after the surgery. In spite of that,
in the patients with R1 resection and positive lymph node, the ad-
juvant chemotherapy improves the survival and reduces recurrence
of the disease [8].
Recurrence of tumor disease is high also after radical resec-
tions and is between 40% and 80% within 5 years after resection [9].
The risk factors include occurrence of satellite metastases, perihilar
affection of lymph node, and perineural dissemination [10,11].
The ablation methods are rarely applied in case of IHCC. This is
due to the ﬁrm consistence of tumor and the size of tumor, which is
often beyond the possibilities of ablation. The same applies for TACE
(Transarterial ChemoEmbolization)withuseof gemcitabine, cisplatin,
oxaliplatin ormitomycin Cwhich are used solely for certain selected
groups of patients withmedian of survival of 12–21months [12,13].
The patients with cholangiocarcinoma must be examined by a
multidisciplinary team and treated according to the individually pre-
pared protocol. As the ﬁrst step, assessing the potential resectability
of tumor is required, because the surgical treatment represents the
optional method for such patients. Cholangiocarcinomas have very
bad prognosis, the 5-year survival is 5%–10%; however, in poten-
tially curative R0 resections, the literature states the survival is 25%–
50%. Therefore, increasing the number of curative resections with
application of adjuvant chemotherapy is required. The most rele-
vant studies on adjuvant chemotherapy of cholangiocarcinomas are
from Japan (ESPAC-3 study) and from Great Britain (BILCAP study).
Adjuvant chemotherapy is recommended for all patients with IHCC
and EHCC, with microscopically positive resection edges and for the
patients after R0 resection with positive lymph node [14].
Although no highly effective adjuvant chemotherapy exists,
gemcitabine is recommended after resection, and according to the
latest studies, it improves the survival. Likewise, the post-operative
radiotherapy improves the survival after R0 and even after R1 re-
sections [15]. In the patients with locally advanced IHCC after R2
resection or primary non-resectable tumor, the surgical treatment
is not indicated, but the patients may beneﬁt from application of
chemoradiation therapywhichmay prolong the survival and improve
the quality of life. Duodenobiliary stents or PTD (percutaneous
transhepatic drainage) are applied as palliative treatment in case
of centrally placed tumors.
5. Conclusion
IHCC represents rare primary tumors of liver, outgrowing from
epithelium of bile ducts. In the CT or MR examination are shown
the image of hypovascular lesion. R0 resection is the optional method
and 5-year survival is between 20% and 60%. Adjuvant chemother-
apy is currently not very effective, but it prolongs the survival mainly
of the patients with R1 resection and positivity of hilar lymph node.
From the surgeon’s aspect, it is important to perform as much R0
resections as possible, because it is currently the most important
factor of improved survival of the patients with IHCC. The pa-
tients with cholangiocarcinoma must be examined by a
multidisciplinary team and treated according to the individually pre-
pared protocol.
Fig. 7. One-year survival of patients according to lymph node positivity.
Fig. 8. Five-year survival of patients according to lymph node positivity.
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